4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7 virus Rigvir administered intramuscularly with a 4-week recovery period

The oncolytic ECHO-7 virus Rigvir was registered in Latvia in 2004 and later in Georgia, Armenia and Uzbekistan. No severe adverse events have been observed. During drug development good laboratory practice (GLP) pre-clinical toxicology studies are generally required by regulatory agencies. Since su...

Descripción completa

Detalles Bibliográficos
Autores principales: Piwoni, Katarzyna, Jaeckel, Gilta, Rasa, Agnija, Alberts, Pēteris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840795/
https://www.ncbi.nlm.nih.gov/pubmed/33537211
http://dx.doi.org/10.1016/j.toxrep.2021.01.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840795/
https://www.ncbi.nlm.nih.gov/pubmed/33537211
http://dx.doi.org/10.1016/j.toxrep.2021.01.009

Ejemplares similares